Germany
· Delayed Price · Currency is EUR Cosmo Pharmaceuticals Statistics
Total Valuation
ETR:C43 has a market cap or net worth of EUR 793.75 million. The enterprise value is 659.75 million.
| Market Cap | 793.75M |
| Enterprise Value | 659.75M |
Important Dates
The next estimated earnings date is Wednesday, July 23, 2025.
| Earnings Date | Jul 23, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.94% |
| Shares Change (QoQ) | +3.31% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 8.52M |
Valuation Ratios
The trailing PE ratio is 5.96.
| PE Ratio | 5.96 |
| Forward PE | n/a |
| PS Ratio | 2.98 |
| PB Ratio | 1.57 |
| P/TBV Ratio | 2.54 |
| P/FCF Ratio | 5.03 |
| P/OCF Ratio | 4.89 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.09, with an EV/FCF ratio of 4.18.
| EV / Earnings | 4.95 |
| EV / Sales | 2.47 |
| EV / EBITDA | 4.09 |
| EV / EBIT | 4.43 |
| EV / FCF | 4.18 |
Financial Position
The company has a current ratio of 4.19, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.19 |
| Quick Ratio | 3.39 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | 0.01 |
| Interest Coverage | 2,809.09 |
Financial Efficiency
Return on equity (ROE) is 29.31% and return on invested capital (ROIC) is 20.39%.
| Return on Equity (ROE) | 29.31% |
| Return on Assets (ROA) | 15.87% |
| Return on Invested Capital (ROIC) | 20.39% |
| Return on Capital Employed (ROCE) | 24.88% |
| Revenue Per Employee | 828,534 |
| Profits Per Employee | 413,776 |
| Employee Count | 322 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 3.27 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.33% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -33.33% |
| 50-Day Moving Average | 59.39 |
| 200-Day Moving Average | 69.38 |
| Relative Strength Index (RSI) | 35.61 |
| Average Volume (20 Days) | 42 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ETR:C43 had revenue of EUR 266.79 million and earned 133.24 million in profits. Earnings per share was 8.12.
| Revenue | 266.79M |
| Gross Profit | 221.43M |
| Operating Income | 148.88M |
| Pretax Income | 153.37M |
| Net Income | 133.24M |
| EBITDA | 160.47M |
| EBIT | 148.88M |
| Earnings Per Share (EPS) | 8.12 |
Balance Sheet
The company has 142.96 million in cash and 2.20 million in debt, giving a net cash position of 140.76 million.
| Cash & Cash Equivalents | 142.96M |
| Total Debt | 2.20M |
| Net Cash | 140.76M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 505.09M |
| Book Value Per Share | 31.12 |
| Working Capital | 153.99M |
Cash Flow
In the last 12 months, operating cash flow was 162.41 million and capital expenditures -4.55 million, giving a free cash flow of 157.86 million.
| Operating Cash Flow | 162.41M |
| Capital Expenditures | -4.55M |
| Free Cash Flow | 157.86M |
| FCF Per Share | n/a |
Margins
Gross margin is 83.00%, with operating and profit margins of 55.81% and 49.94%.
| Gross Margin | 83.00% |
| Operating Margin | 55.81% |
| Pretax Margin | 57.49% |
| Profit Margin | 49.94% |
| EBITDA Margin | 60.15% |
| EBIT Margin | 55.81% |
| FCF Margin | 59.17% |
Dividends & Yields
This stock pays an annual dividend of 2.00, which amounts to a dividend yield of 4.00%.
| Dividend Per Share | 2.00 |
| Dividend Yield | 4.00% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | 24.09% |
| Buyback Yield | -1.94% |
| Shareholder Yield | 2.06% |
| Earnings Yield | 16.79% |
| FCF Yield | 19.89% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ETR:C43 has an Altman Z-Score of 7.21.
| Altman Z-Score | 7.21 |
| Piotroski F-Score | n/a |